Product expected to be available within six weeks LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today […]

by

By Stephanie Garr CBD oil is a natural remedy derived from the cannabis plant. As the source of both marijuana and hemp, any substance made from cannabis immediately raises concerns around its legality and safety. However, certain components of the cannabis plant can be beneficial for health and healing, without getting you “high.” CBD oil […]

by

The “comforting fictions” of dementia care are the focus of a New Yorker article. Pimavanserin (Nuplazid) did not carry a significant different mortality risk than quetiapine (Seroquel) or the combination of both medications among patients with Parkinson’s disease psychosis, UC San Diego researchers reported. (Neurology) The DEA placed FDA-approved cannabidiol products containing no more than […]

by

The “comforting fictions” of dementia care are the focus of a New Yorker article. Pimavanserin (Nuplazid) did not carry a significant different mortality risk than quetiapine (Seroquel) or the combination of both medications among patients with Parkinson’s disease psychosis, UC San Diego researchers reported. (Neurology) The DEA placed FDA-approved cannabidiol products containing no more than […]

by

The launch of a Phase 1 clinical study to test the safety of Emerald Health Pharmaceuticals’ EHP-101, a cannabidiol-based oral formulation, in healthy volunteers has been announced. EHP-101 is a potential treatment for scleroderma and multiple sclerosis. The drug was designed to enhance the effectiveness of cannabidiol, the active ingredient of marijuana, and help curb neuroinflammation, […]

by

SAN DIEGO, CA, Sept. 27, 2018 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced the initiation of enrollment of its Phase I clinical trial of EHP-101, an oral formulation of a patented, synthetic new chemical entity (NCE) derived from cannabidiol (CBD) and chemically modified to […]

by

Emerald Health Pharmaceuticals announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability of EHP-101, a potential cannabidiol treatment for multiple sclerosis (MS) and scleroderma. The randomized, double-blind, and placebo-controlled study (ACTRN12618001390279p) will  investigate the safety and pharmacokinetics (how the body processes a medicine) of EHP-101, a cannabidiol (CBD) […]

by

Everybody will respond differently to cannabis. What we can do is guide people and provide them with enough information so that they can experiment (or feel comfortable experimenting) to find what really works for them. … read more at: https://www.refinery29.com/en-us/2018/09/209594/budtender-cannabis-marijuana-industry-emma-chasen

by

Project CBD, a California-based educational non-profit, has published an in-depth Primer on Cannabinoid-Drug Interactions for health professionals, patients, and public policy-makers. The 33-page report, summarized below, is available for free download at the bottom of the page. Drug interactions are a significant consideration in modern medicine. More than half of U.S. adults regularly take prescription meds […]

by

There has been quite a lot of big news coming out involving cannabis as of late, with much of this news being in regard to clinical trials and government approvals. All of these clinical trials are helping to further our knowledge of cannabis’s potential medical benefits and safety as a medication, and they are opening […]

by

The faces of Dravet Syndrome.What Does the Ruling Mean for Most School Districts Nationwide? It appears that many individual school districts, especially in medical marijuana-approved states, will now be forced to suddenly begin the evaluation process of whether districts will have to allow the new prescription pharmaceutical to be used on school grounds and buses. […]

by

Project CBD, a California-based educational non-profit, has published an in-depth Primer on Cannabinoid-Drug Interactions for health professionals, patients, and public policy-makers. The 33-page report, summarized below, is available for free download at the bottom of the page. Drug interactions are a significant consideration in modern medicine. More than half of U.S. adults regularly take prescription meds […]

by

Treatment with EHP-102, an investigational cannabinoid-derived medicine, reduced weight loss, preserved motor neurons of the spinal cord, and lowered the abnormal reactivity of astroglial cells in a mouse model of amyotrophic lateral sclerosis (ALS), new research shows. Findings were recently published in the study, “Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an […]

by